

APIs current market trends: Middle East & Africa

DR SANJAY AGRAWAL

ESTIMATIONS made on the Middle East and Africa Active Pharmaceutical Ingredients, intermediates market expect to gain market growth within 2021 to 2028. The data market research analysis is growing with a CAGR of 18.6 % in the upcoming forecast period of 2021 to 2028, reaching more than millions by 2028. The extensive burden of chronic disorder and an increase of the aging population with significant divisions have propelled the demand in the market.

The well-established healthcare services, suitable manufacturing units, and higher spending of power based on technological growth have made API access to the manufacture and rise of target therapy more prominent. The stringent regulatory framework creates effective results. The European Union and other countries have started adopting the fierce regulatory requirements to enforce the active pharmaceutical ingredient inspection system to a level of FDA for a standardised regulatory work at a global range.

Overview of Active Pharmaceutical Ingredients (APIs) and trends

APIs are substances or combinations of substances meant to be used to manufacture a prescription product and become active pharmaceutical ingredients when used in the manufacture of the drug. Such substances provide pharmacological activity. The APIs and excipients are used to make the final drug dosage type, but the APIs are made from raw materials known as intermediates.

API intermediates are the materials that are created during the API phase. Intermediates are by-products of active pharmaceutical ingredients that have similar therapeutic and medicinal properties to APIs. These intermediates are often used to treat various chronic diseases, including cancer, respiratory diseases, and bacterial infections.

Agents or compounds used as raw materials in the formulation or manufacture of active pharmaceutical ingredients are referred to as API intermediates. In final API, these intermediates undergo refinement or molecular changes. The development of intermediates involves various technologies, including amination, alkoxylation, electrochemistry, hydrogenation, hydroformylation, acetylene chemistry, phosgene chemistry and so on.

With the rising prevalence of various chronic disorders and the aging population, the API intermediates market is growing. Increased research and development in pharmaceutical APIs and intermediates are also propelling the API intermediates market forward.

The API intermediates market report ex-

amines market share, new technologies, and product pipeline review, as well as the influence of domestic and localised market players, emerging revenue pockets, changes in market legislation, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations.

API Management Market Scope and Size in the Middle East and Africa

The API management market comprises four categories: component, deployment type, company size, and industry. The growth of segments allows you to analyse niche pockets of growth and business approaches and identify your possible critical applications and target market differences.

- Based on this part, the API management market has been divided into solutions and services. API interface, API analytics, and security are the three sub-categories of the solution.

API framework is divided into four categories: API portal, API gateway, API management, and API monetisation. Integration and implementation, consultation, care and maintenance, training, and education are the sub-categories of services.

- The API management market is divided into on-premises and cloud implementation types.
- API management is divided into two categories based on the company's size: small and medium businesses and large businesses.
- The API management sector is divided into banking, financial services, insurance, IT and telecommunications, government, healthcare, life sciences, warehousing and distribution goods, media and entertainment, travel and transport, manufacturing, and other industries.

Analysis of the API Management Market at the Country

Level

The API management market is examined, and market size and volume data are given by region, part, deployment type, organisation size, and industry. Saudi Arabia, the United Arab Emirates, South Africa, Egypt, Israel, and the rest of the Middle East and Africa are among the countries covered in the Middle East and Africa API management market study (MEA).

Saudi Arabia is projected to expand at a moderate pace in the Middle East and Africa API management sector because only a few businesses in the area have a digital presence, resulting in API management market growth.

Individual API management industry impacting factors and changes in regulation in the domestic market also discussed, which affect the market's current and future trends. Downstream and upstream supply chain analysis, technical developments and Porter's five forces analysis, and case studies are only a few of the data points used to forecast

CONTINUED ON p20▶



Medisearch Laboratories
(Bombay) Pvt. Ltd.

**STABILIZED OXYCHLORO
COMPLEX (HPLR)**

Produced in **Technical collaboration**
with ERC Biolabs (UK).

Meets the stringent
European Pharmacopeia Criteria.

**COA, MSDS, MOA and
European PET data available.**

Exported to various countries including EU.



Contact: medisearchsoc@gmail.com

Kenya has encouraged zero-rated imports

CONTINUED FROM p19 ▶

With the road map of PMPA, the African Medicines Regulatory Harmonisation (AMRH) initiative was established in 2009 and helped build a regulatory environment for the development of a more robust pharmaceutical sector. To achieve this aim, AMRH works towards improving medicine registration processes and operational inefficiencies, thereby reducing registration times whilst enhancing the quality of the registration decision.

The programme is implemented under the Industrialisation, Science, Technology and Innovation unit of the NEPAD Agency, which is the implementation and technical arm of the African Union (AU).

Kenya stood as the current leading producer of pharmaceutical products in the Common Market for Eastern and Southern Africa (COMESA) region. Kenya also became the

3rd largest exporter of pharmaceuticals in Africa. The pharmaceutical industry in Kenya supplies approximately one-quarter of the local market.

Kenyan Government is supporting the pharmaceutical industry by establishing Export processing zones (EPZs), that offer an encouraging environment for promotion and facilitation of export oriented investments. Kenya Government has also established policies to streamline the processes and encourage investors and stakeholders to encourage pharmaceutical industries in their country.

Even though Kenya is doing its best for improved pharmaceutical industry, the Ministries of Health and Industrialisation and Trade & Enterprise development in collaboration with the International Finance Collaboration (IFC) found the dependency of country on imported inputs, which hiked the cost of logistics, utilities, and packaging materials.

However, to overcome such costs and to encourage further, Government of Kenya has encouraged zero-rated imports of raw materials and finished pharmaceutical products. This policy has supported the local manufacturing of pharmaceuticals.

Overall, the efforts of African countries especially Kenya to earmark its strength in establishment of pharmaceutical industry is highly appreciable. Its journey of imparting all the available policies to fulfil its local market needs for better health is an inspiring one. ○

(Kumar is associate professor and IQAC coordinator, Shri Vishnu College of Pharmacy, Bhimavaram, AP. Rao is vice-principal and professor, Department of Pharmaceutics, K L College of Pharmacy, Koneru Lakshmaiah Education Foundation Deemed to be University, Guntur, AP. They can be reached at vsaikumar@gmail.com)

China is significant supplier of APIs

CONTINUED FROM p17 ▶

business scenarios for individual countries.

While providing forecast analysis of the country data, the role and availability of the Middle East and Africa brands, and the challenges they face due to significant or scarce competition from local and domestic brands, the influence of domestic tariffs and trade routes is all taken into account.

The API management business competition landscape lists each competitor in detail. The business summary, financials, revenue produced, market opportunities, investment in R&D, new market strategies, Middle East and Africa presence, company strengths and weaknesses, product launch, product width and breadth, application dominance are among the details included.

The Market for APIs Has Been Affected by the Covid-19 Outbreak

Covid-19 has harmed any market of the Middle East and Africa as well as the global economy. Pharmaceuticals is one sector that has suffered from Covid-19's wrath. It has wreaked havoc on the pharmaceutical indus-

try's manufacturing and supply chain.

China is a significant supplier of active pharmaceutical ingredients. Since China was at the epidemic's epicentre, halt of all production and export, and factories were shut down to prevent the virus from spreading all across. Furthermore, as the virus spreads to the other 100 countries worldwide, it affects the manufacture and export-import of APIs from other significant nations such as the United States and India. Based on the current FDA, China has 15% of the world's API manufacturing facilities for 370 essential drugs, while the United States has 21% of those operations.

In the Hubei province, where Covid-19 existed, there have been 44 FDA-approved companies that manufacture APIs or supply chemical ingredients to API manufacturers, including Puracap Pharmaceutical LLC and Fresenius Kabi, AG. These firms are shut down since the lockdown, preventing API manufacturing and import-export in and around China. There is no presence of any API in Africa. All the manufactured medicines and vaccines are transported from the

outside world. The situation is harsh and costly for regions like Africa.

Conclusion

Countries in the Middle East and Africa are experiencing a challenging situation with the possibility of growth shortly. The problem is highly dependent on other nations for the absence of API in the region, especially in Africa. Drugs such as anti-infective, diabetes, cardiovascular, analgesics, and pain relief drugs have historically dominated the APIs market.

Nevertheless, demand is moving toward complex APIs used in novel formulations that target niche therapeutic areas, according to R&D developments. Drug price control policies in nations of the Middle East and Africa, huge competition among emerging players, and stringent regulatory policies are among the main factors limiting future growth. With Covid, the entire system in Middle East & Africa has seen a devastating up and down, although the focus on improvements is still on the marking for effective results. ○

(The author is a leading pharmaceutical consultant)

Global pandemic has prioritised spending

CONTINUED FROM p18 ▶

ments, international organisations, and NGOs for the provision of medical equipment and infrastructural support. At the same time, Iran has sought to raise its profile as a regional leader in pharmaceutical development and has taken every opportunity to showcase the latest developments in Covid-19 vaccines, bio-

technology, and traditional medicine.

The global pandemic has prioritised spending on fighting Covid-19, reducing allocations for other essential medicine to treat other diseases. However, this is considered a temporary shift, while the pandemic has strengthened international cooperation both to combat Covid-19 and within the pharmaceuticals sector

in general. In Iran, the pandemic is responsible for Fast Track Approvals for Covid-19-Related Treatments by the IML and Medicine Registration Process. ○

(The author is assistant professor, Joginpally BR Pharmacy College, Hyderabad, Telangana. She can be reached at praveenadev@gmail.com)